Item

Magnetic resonance spectroscopy metabolites as biomarkers of Alzheimer’s Disease

Abstract
Abstract Background Magnetic resonance spectroscopy (MRS) is a non-invasive method of evaluating metabolite levels in the cerebral cortex. Measurable metabolites can provide markers of neuronal damage, glial activation and, neurotransmission, pathological features of Alzheimer’s disease. Here we sought to establish the effectiveness of several metabolites as biomarkers for Alzheimer’s disease. Method 198 participants with a single-voxel 1H MRS scan were enrolled (n = 170 participants living with Alzheimer’s disease, n = 28 healthy controls). All participants underwent 3-tesla magnetic resonance imaging and cognitive assessment with the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-cog). An experienced radiographer placed an 8cm3 voxel within the posterior cingulate cortex for single-voxel 1H MRS acquisition. Scans were then processed to evaluate levels of N-acetylaspartate, myo-inositol, choline, and glutamate. Creatine peak was additionally evaluated as a reference. N-acetylaspartate/creatine, myo-inositol /creatine, choline/creatine ratios and glutamate were compared between Alzheimer’s participants and controls to calculate the effect size. Correlations were then performed between metabolite ratios and ADAS-cog scores. Result N-acetylaspartate/creatine effectively distinguished between Alzheimer’s patients and healthy controls (Cohens D = 0.83) with a lowered ratio in Alzheimer’s participants. Elevated glutamate signal and myo-inositol/creatine ratios were also displayed in Alzheimer’s patients (Cohens D = 0.62 and 0.69, respectively). Choline/creatine ratio displayed no significant difference between groups (Cohens D = 0.26). Lower N-acetylaspartate /creatine and glutamate correlated with higher ADAS-cog scores (r = -0.29, p < 0.001, CIs: -0.42 to -0.14 and r = -0.30, p < 0.001, CIs: -0.44 to -0.16, respectively). Myo-inositol and choline failed to correlate with cognitive impairment. Conclusion N-acetylaspartate, a signature of neuronal damage, is an effective biomarker of Alzheimer’s disease and associated cognitive decline. Enhanced glial activity, measured with myo-inositol, was shown in Alzheimer’s disease, suggesting that glial-reactivity markers deserve consideration in the diagnosis of Alzheimer’s disease. Glutamate demonstrated the strongest association with cognitive impairment, despite showing a smaller effect size than N-acetylaspartate and myo-inositol in distinguishing between Alzheimer’s patients and controls. Together we establish MRS is a useful, non-invasive biomarker of several pathological processes involved in the development of Alzheimer’s. Evaluation of N-acetylaspartate, glutamate, and myo-inositol may aid in the diagnosis of neurodegenerative disease, detecting markers undetectable by conventional MRI methodology.
Author
Nowell, Joseph
Young, Megan
Femminella, Grazia Daniela
Ritchie, Craig W
Holmes, Clive
Walker, Zuzana
Ridha, Basil H
Lawrence, Robert M
McFarlane, Brady
Archer, Hilary
Coulthard, Elizabeth
Underwood, Benjamin
Koranteng, Paul
Karim, Salman
Prasanna, Aparna
Junaid, Kehinde
McGuinness, Bernadette
Nilforooshan, Ramin
Thacker, Simon
Russell, Gregor
Malik, Naghma
Mate, Vandana
Knight, Lucy
Kshemendran, Sajeev
Holscher, Christian
Harrison, John E
Hinz, Rainer
Tadros, George
Passmore, Anthony Peter
Ballard, Clive G
Edison, Paul
Citations
Altmetric:
Date
2023
Type
Conference Proceeding
Subject
Alzheimer disease, Magnetic resonance spectroscopy
Collections
NottsHC Dementia
Show all metadata
Citation
Nowell, J., Young, M., Femminella, G. D., Ritchie, C. W., Holmes, C., Walker, Z., Ridha, B. H., Lawrence, R. M., McFarlane, B., Archer, H., et al. (2023). Magnetic resonance spectroscopy metabolites as biomarkers of Alzheimer’s Disease. In: Wilcock, D. M., (Ed.) Alzheimer's Association International Conference 2023, 2023 Amsterdam. Alzheimer's and Dementia, p.e077775.
Journal / Source Title
DOI
URI
https://mider.dspace7.openrepository.com/handle/20.500.12904/19960
PMID
Publisher
Alzheimer's Association
Publisher’s URL
Publisher’s statement
Note / Copyright